ClinicalTrials.gg
CompletedNCT06151197STRIDEUpdated Oct 14, 2026

Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease)

A Phase 3 interventional study of EN3835 and Placebo in Plantar Fibromatosis and Ledderhose Disease, sponsored by Endo USA Inc., a Keenova Therapeutics Company. Completed at 66 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Endo USA Inc., a Keenova Therapeutics Company (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will assess the efficacy, safety, and tolerability of EN3835 compared to placebo in the treatment of PFI (also known as Ledderhose disease).

02

Conditions studied

  • Plantar Fibromatosis
  • Ledderhose Disease
03

In context

Lead sponsor

Endo USA Inc., a Keenova Therapeutics Company is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Be an ambulatory male or female ≥18 years of age.
  • Have a diagnosis of PFI.
  • Have current foot pain due to PFI.
  • Agree not to use prohibited medication, throughout the study, and not use any medication to treat PFI pain, except as permitted per the protocol.
  • If female, be of non- (history of hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or with no history of menstrual flow in the 12 months prior to the Screening Visit); or, if of childbearing potential, be non-pregnant, non-lactating and agree to use effective when with a male partner for the duration of the study and for 28 days after any active treatment period.
  • Be capable of providing consent, are adequately informed, and understand the nature and risks of the study.

Key Exclusion Criteria:

  • Has the presence of non-PFI-related nodules on the foot (for example, neurofibroma, rhabdomyosarcoma, liposarcoma, neurilemmomas, rheumatoid nodules, desmoid tumors, or malignant soft tissue lesions of the foot or ankle).
  • Has any musculoskeletal, neuromuscular, neurosensory, other neurological or related disorder that affects the participant's use of his or her foot and/or would impair his/her completion of study assessments as determined by the investigator.
  • Has any significant medical history or examination findings related to the participant's plantar nodule(s), which in the investigator's opinion, would make the participant unsuitable for study intervention administration or required assessments and evaluations.
  • Has a known bleeding disorder which would make the participant unsuitable for enrollment in the study.
  • Has a laboratory abnormality.
  • Has concurrent diseases that might interfere with the conduct of the study, confound the interpretation of the study results or endanger the participant's well-being, or any significant hematological, endocrine, cardiovascular, respiratory, renal, hepatic, or gastrointestinal disease. If there is a history of such disease but the condition has been stable for greater than 1 year and is judged by the investigator not to interfere with participation in the study, the participant may be included, with the documented approval of the medical monitor.
  • Has any other significant medical condition(s), which in the investigator's opinion, would make the participant unsuitable for enrollment in the study.
  • Is pregnant or plans to become pregnant.
  • Is breastfeeding or is providing or plans to provide breast milk in any manner during the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
436 participants (actual)

Study arms

  • Experimental
    EN3835

    Biological: EN3835

  • Placebo comparator
    Placebo

    Other: Placebo

Interventions

  • BiologicalEN3835

    Biologic: EN3835 injection

  • OtherPlacebo

    Placebo injection

06

What researchers measure

Primary outcomes

  1. Change from Baseline to Week 12 in the Weekly Mean of the Average Daily (24-hour) Pain (ADP) Score as Measured on the Pain Intensity Numeric Rating Scale (NRS)

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change from Baseline in the Foot Function Index (FFI) Difficulty Subscale Score

    Time frame: Baseline, up to Day 85

  2. Change from Baseline in the FFI Activity Limitation Subscale Score

    Time frame: Baseline, up to Day 85

  3. Change from Baseline in the FFI Pain Subscale Score

    Time frame: Baseline, up to Day 85

  4. Change from Baseline in the FFI Total Score

    Time frame: Baseline, up to Day 85

  5. Number of Participants That Used Rescue Analgesic Medication

    Time frame: Up to Day 85

  6. Amount of (milligrams [mg]) Rescue Analgesic Medication Used

    Time frame: Up to Day 85

  7. Patient Global Impression of Change (PGIC) Foot Pain Score

    Time frame: Up to Day 85

  8. Patient Global Impression of Severity (PGIS) Score

    Time frame: Up to Day 85

  9. Clinician Global Impression of Change (CGIC) Score

    Time frame: Up to Day 85

  10. Subject Satisfaction Score

    Time frame: Up to Day 85

  11. Change from Baseline in Nodule Consistency (Firmness)

    Time frame: Baseline, up to Day 85

  12. Change from Baseline in the Nodular Hardness of the Treated Nodules

    Time frame: Up to Day 85

07

Study locations

66 sites
  • Endo Site 42
    Mesa, Arizona 85210, United States
  • Endo Site 64
    Scottsdale, Arizona 85260, United States
  • Endo Site 11
    Tucson, Arizona 85712, United States
  • Endo Site 49
    Castro Valley, California 94546, United States
  • Endo Site 39
    Cerritos, California 90703, United States
  • Endo Site 31
    Corona, California 92882, United States
  • Endo Clinical Site 2
    Encinitas, California 92024, United States
  • Endo Site 8
    Fresno, California 93710, United States
  • Endo Site 28
    Lancaster, California 93534, United States
  • Endo Site 9
    Los Angeles, California 90010, United States
  • Endo Site 53
    Los Angeles, California 90063, United States
  • Endo Site 50
    San Francisco, California 94115, United States
  • Endo Site 29
    Sherman Oaks, California 91403, United States
  • Endo Site 30
    Tarzana, California 91356, United States
  • Endo Site 61
    Torrance, California 90502, United States
  • Endo Site 47
    Johnstown, Colorado 80534, United States
  • Endo Site 65
    Parker, Colorado 80134, United States
  • Endo Site 17
    Westminster, Colorado 80031, United States
  • Endo Site 22
    Hialeah, Florida 33013, United States
  • Endo Site 59
    Jacksonville, Florida 32209, United States
  • Endo Site 23
    Miami, Florida 33126, United States
  • Endo Site 26
    Miami, Florida 33156, United States
  • Endo Site 21
    Miami, Florida 33184, United States
  • Endo Site 35
    North Miami Beach, Florida 33169, United States
  • Endo Site 19
    Palm Beach Gardens, Florida 33410, United States
  • Endo Clinical Site 1
    Pinellas Park, Florida 33782, United States
  • Endo Site 14
    Plantation, Florida 33317, United States
  • Endo Site 60
    Sweetwater, Florida 33172, United States
  • Endo Site 33
    Virginia Gardens, Florida 33166, United States
  • Endo Site 24
    Lawrenceville, Georgia 30043, United States
  • Endo Site 27
    O'Fallon, Illinois 62269, United States
  • Endo Site 45
    Oak Brook, Illinois 60523, United States
  • Endo Site 54
    Overland Park, Kansas 66211, United States
  • Endo Site 56
    Shreveport, Louisiana 71101, United States
  • Endo Site 5
    Pasadena, Maryland 21122, United States
  • Endo Site 16
    Grand Rapids, Michigan 49525, United States
  • Endo Site 12
    Jefferson City, Missouri 65109, United States
  • Endo Site 51
    Billings, Montana 59101, United States
  • Endo Site 36
    Missoula, Montana 59804, United States
  • Endo Site 34
    Oradell, New Jersey 07649, United States
  • Endo Site 62
    Vineland, New Jersey 08360, United States
  • Endo Site 15
    Durham, North Carolina 27704, United States
  • Endo Site 20
    Wilmington, North Carolina 28412, United States
  • Endo Site 63
    Oklahoma City, Oklahoma 73102, United States
  • Endo Site 10
    Altoona, Pennsylvania 16602, United States
  • Endo Site 44
    Malvern, Pennsylvania 19355, United States
  • Endo Site 38
    State College, Pennsylvania 16801, United States
  • Endo Site 48
    Arlington, Texas 76015, United States
  • Endo Site 3
    Bedford, Texas 76021, United States
  • Endo Site 43
    Burleson, Texas 76028, United States
  • Endo Site 25
    Dallas, Texas 75208, United States
  • Endo Site32
    Fort Worth, Texas 76104, United States
  • Endo Site 7
    Georgetown, Texas 78628, United States
  • Endo Site 55
    Houston, Texas 77027, United States
  • Endo Site 40
    Humble, Texas 77338, United States
  • Endo Site 4
    McAllen, Texas 78501, United States
  • Endo Site 46
    San Antonio, Texas 78224, United States
  • Endo Site 18
    San Antonio, Texas 78251, United States
  • Endo Site 37
    San Antonio, Texas 78258, United States
  • Endo Site 41
    Bountiful, Utah 84010, United States
  • Endo Site 6
    Salt Lake City, Utah 84107, United States
  • Endo Site 52
    Falls Church, Virginia 22042, United States
  • Endo Site 13
    Suffolk, Virginia 23434, United States
  • Endo Site 70
    Mayagüez, 00680, Puerto Rico
  • Endo Site 68
    Mayagüez, 00682, Puerto Rico
  • Endo Site 69
    Ponce, 00716, Puerto Rico
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jun 2026, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Nov 30, 2023
StartActual
Nov 28, 2023
Primary completionActual
Jun 9, 2026
CompletionActual
Jun 9, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Secondary outcomes
1 added
What changed in the outcomes
  • AddedPatient Global Impression of Severity (PGIS) ScoreTime frame: Up to Day 85
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedPatient Global Impression of Severity (PGIS) ScoreTime frame: Up to Day 85
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06151197
Responsible party
Sponsor
First posted
Nov 30, 2023
Start date
Nov 28, 2023
Primary completion
Jun 9, 2026
Completion
Jun 9, 2026
Last update
Oct 14, 2026

Study contacts

Louis Ortega
study director · Endo USA Inc., a Keenova Therapeutics Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Microbial Collagenase

Start the discussion